Thursday, October 22, 2020
8:30AM – 9:30 AM ET
This virtual program is at 8:30AM Eastern, 7:30AM Central, 6:30AM Mountain, and 5:30AM Pacific.
- Online Personalized Poster Portal
- Interactive, case-based learning environment
Adam M. Brufsky, MD, PhD
Professor of Medicine
University of Pittsburgh
This CME initiative is designed to meet the educational needs of medical oncologists, advanced practice clinicians, oncology nurses, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
On completing the program, attendees should be able to:
- Identify the patient who will benefit from CDK 4/6 inhibitor therapy with consideration of patient and disease characteristics and appropriately time its use in the course of the disease
- Recognize commonly associated toxicities of CDK4/6 inhibition, and apply strategies for both the monitoring and management of adverse events associated with their use in patients with metastatic breast cancer
- Utilize methodologies to activate all members of the healthcare team, encourage collaboration, and incorporate shared-decision-making and survivorship tools to assist in optimizing patient outcomes and management of adverse events
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the care of patients with with hormone receptor-positive, HER2-negative metastatic breast cancer
1.0 ANCC Contact Hours
CNE ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com